Abstract

With over 1 million deaths annually attributed to malaria, an effective vaccine is an urgently needed intervention. However, the various stages of the malaria parasite lifecycle have differing protective immune mechanisms and clinical endpoints, and usually different, often polymorphic, antigens. Trials using an increasing variety of vaccine platforms and antigens are under way in an attempt to achieve this long-awaited goal.

Author affiliations

1. Stephen M. Todryk is at the Cente for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, UK.
2. Adrian V. S. Hill is at the Centre for Clinical Vaccinology and Tropical Medicine and Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Churchill Hospital, Oxford, UK.

Correspondence to: Stephen M. Todryk¹ Email: stephen.todryk@ndm.ox.ac.uk

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.